Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Vertex Pharmaceuticals ( VRTX) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 1.1%. By the end of trading, Vertex Pharmaceuticals fell $0.86 (-1.0%) to $83.95 on average volume. Throughout the day, 1,241,388 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 1,601,900 shares. The stock ranged in price between $83.76-$85.29 after having opened the day at $85.29 as compared to the previous trading day's close of $84.81. Other companies within the Health Care sector that declined today were: Oculus Innovative ( OCLS), down 11.8%, Five Prime Therapeutics ( FPRX), down 10.1%, Cardiome Pharma Corporation ( CRME), down 5.9% and Mesa Laboratories ( MLAB), down 5.8%. Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Vertex Pharmaceuticals has a market cap of $19.8 billion and is part of the drugs industry. Shares are up 14.2% year to date as of the close of trading on Friday. Currently there are 13 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold. TheStreet Ratings rates Vertex Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income and revenue growth. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, weak operating cash flow and feeble growth in the company's earnings per share.
- You can view the full Vertex Pharmaceuticals Ratings Report.
- Use our health care section to find sector-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.